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Increasing prevalence of bacteria that carries resistance towards conventional antibiotics has prompted 11 
the investigation into new compounds for bacterial intervention to ensure efficient infection control in 12 
the future. One group of potential lead structures for antibiotics is antimicrobial peptides due to their 13 
characteristics as naturally derived compounds with antimicrobial activity. In this study we aimed at 14 
characterizing the mechanism of action of a small set of in silico optimized peptides. Following 15 
determination of peptide activity against E. coli, S. aureus and P. aeruginosa, toxicity was assessed 16 
revealing meaningful selectivity indexes for the majority of the peptides. Investigation of the peptides 17 
effect on bacteria demonstrated a rapid growth inhibition with signs of bacterial lysis together with 18 
increased bacterial size. Both visual and quantitative assays clearly demonstrated bacterial membrane 19 
disruption after 10 minutes for the most active peptides. The membrane disrupting effect was verified 20 
by measuring the release of calcein from bacterial mimicking liposomes. This revealed the most active 21 
peptides as inducers of immediate release, indicating the kinetics of membrane permeabilization as an 22 
important determinant of bacterial activity. No well-defined secondary structure of the peptides could 23 
be determined using CD-spectroscopy in the presence of different liposomes mixtures, implying that 24 
there is no correlation between peptide secondary structure and the observed anti-bacterial and 25 
cytotoxic activity for this set of peptides. In conjunction, these findings provide strong indications of 26 
membrane disruption as the primary mechanism of bacterial growth inhibition for the tested peptides. 27 
 28 
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For a long time, the treatment of most infections in western countries has been considered a rather 33 
uncomplicated matter due to the effectiveness of various antibiotics. Fortunately that still applies, 34 
although the treatment of some bacterial infections has become gradually more complicated in recent 35 
years because of the increase in bacterial resistance against conventional antibiotics. This is made 36 
obvious by the fact that infectious diseases are the third leading cause of death in developed countries, 37 
despite the abundant availability of antibiotics 1.  38 
The emergence of bacteria with resistance towards conventional antibiotics is increasing at an alarming 39 
rate especially in hospital settings, seriously hampering effective treatment of infections 2. Methicillin-40 
resistant Staphylococcus aureus (MRSA) was in 2005 estimated to have caused 94 000 infections 41 
leading to 19 000 deaths 3 and together with other multi drug resistant (MDR) strains of Pseudomonas 42 
aeruginosa and extended-spectrum-beta-lactamase (ESBL) producing Klebisella pneumonia and 43 
Escherichia coli, they pose an increasing threat to public health 4. On top of this there has only been 44 
introduced a very limited number of new antibacterial agents to the market since the 60’s which 45 
together with a rapid declining interest from medical companies into development of new antibiotics, 46 
illustrates a development that calls for concern 2, 4. In that perspective, it is important to pursue the 47 
development of new antimicrobial agents, with a novel mode of action, to ensure that we will be able to 48 
cure life-threatening infections in the future. One such group of compounds that has the potential to 49 
assist in the fight against infections is antimicrobial peptides.  50 
Antimicrobial peptides are a natural component of the innate immune system in a wide range of 51 
organism, acting as a first line of defense against various microbes. These peptides have been isolated 52 
from a great number of organisms ranging from bacteria to plants, invertebrates and vertebrates, 53 
thereby demonstrating their prevalence in virtually all branches of life 5. In relation to their abundance 54 
among different kinds of organisms, the biological effect varies from direct bacterial inhibition 5 to 55 
immune modulating 6, proving their versatility as effector molecules. The variety in origin and 56 
biological effect is reflected in the characteristics of antimicrobial peptides having a great deal of 57 
diversity, in both primary and secondary structure, probably explaining their evolutionary success 7. 58 
Even so, there are a number of structural similarities that apply for most antimicrobial peptides, usually 59 
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being relatively short, ranging from 12-50 amino acids, carrying a net positive charge of +2 to +9 and 60 
having a distinct proportion of hydrophobic residues 8.  61 
The positive charge of antimicrobial peptides is generally accepted as the main feature that mediates 62 
selectivity towards bacteria by harboring sufficient electrochemical attraction towards the negatively 63 
charged outer entities of bacterial cells to allow selective activity. As natural compounds with an 64 
antimicrobial effect, antimicrobial peptides have drawn the attention of scientist to investigate their 65 
potential as future antimicrobial agents. This has led to the identification of more than 1000 66 
antimicrobial peptides 9, and numerous attempts to improve activity by modifying natural antimicrobial 67 
peptides or the de novo design of antimicrobial peptides 10 including the use of unnatural amino acid 68 
analogues 11. Although a large number of natural and synthetic antimicrobial peptides have been 69 
studied, there are still today, questions tied to the exact nature of bacterial inhibition exerted by these 70 
peptides. Compiling evidence suggests that antimicrobial peptides have a plethora of effects against 71 
bacteria, ranging from unspecific membrane perforation to specific inhibition of intracellular targets 72 
and the bacterial inhibition exerted by some antimicrobial peptides is possibly the result of more than 73 
just one isolated mechanism 5. Although different targets have been identified, a detailed 74 
characterization of the mode of action has only been carried out on a minority of peptides. To truly take 75 
advantage of antimicrobial peptides and make use of their potential as lead structures for bacterial 76 
intervention, it is therefore in that perspective that the scope of this work is to elucidate the mechanism 77 
of action of a set of different synthetic antimicrobial peptides. The antimicrobial peptides used in this 78 
study were originally designed by Fjell and colleagues by the use of in silico screening 12. The 10 most 79 
active peptides from this optimization were selected for investigation in this study, all having a positive 80 
charge of +4, uniform chain length of 9 amino acids and at least three tryptophan residues. To verify 81 
the activity of the peptides, minimal inhibitory concentration (MIC) testing was carried out against E. 82 
coli, P. aeruginosa and S. aureus reference strains and the two most active peptides were selected for 83 
further studies to elucidate the mechanism of bacterial inhibition. Herein we demonstrate compelling 84 
evidence for membrane perforation as the main contributor of bacterial inhibition together with 85 
reversible metabolic disturbance at lower concentrations. 86 
87 
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Material and methods 88 
Solid phase peptide synthesis 89 
The peptides were synthesized using solid phase Fmoc chemistry with amidation on the carboxyl end, 90 
purified by reverse-phase HPLC using a C18 column (Higgins Analytical Inc. 10 µm 250x10 mm) and a 91 
water/acetonitile gradient. The correct mass and purity >95% was verified using Dionex Ultimate 3000 92 
RP-UHPLC (C18 Kinetex 100 x 2.1 mm, 100 Å) electrospray ionization mass spectrometry (Finnigan 93 
LTQ) (Figure S1, Table S1). 94 
 95 
Minimal inhibitory concentration determination 96 
The antimicrobial efficacy of peptides was tested using a serial dilution titration, as previously 97 
described 13 on a panel of clinically relevant bacterial strains; i.e. E. coli (ATCC 25922), P. aeruginosa 98 
PAO1 (ATCC 15692), S. aureus (ATCC 29213). Conventional antibiotics used throughout the study 99 
include Ampicillin (A9518), Ciprofloxacin (17850), Tetracycline (T7660), Tobramycin (T4014) and 100 
Polymyxin B (92301), all purchased from Sigma. In short, overnight cultures were grown to mid-log 101 
phase before diluting to ~5×105 CFU/mL in Mueller Hinton broth (Becton Dickinson) and 90 µL was 102 
used to inoculate each well of a 96-well polypropylene plate (Cat. No. 3879, COSTAR). Then, 10 µL 103 
aliquots of a 2-fold dilution series of the peptides were added and the minimal inhibitory concentration 104 
(MIC) was scored as the lowest concentration that inhibited visible growth after 48 hours of incubation 105 
at 37°C.  106 
 107 
Hemolysis assay 108 
Freshly drawn human blood with EDTA as anticoagulant was washed and centrifuged at 500 g for 5 109 
minutes until the appearance of clear supernatant. A two-fold dilution series of peptides was added to 110 
96-well polypropylene microtiter plates (COSTAR Cat. No.3879) in 75 µL aliquots together with 50 111 
µL of 4 % final concentration of red blood cells (RBC) giving a total volume of 125 µL. The plate was 112 
incubated with shaking for 1 hour at 37°C, before being centrifuged at 250 g for 5 minutes. 50 µL of 113 
the supernatant was diluted 1:3 in sterile saline in a flat bottomed 96-well greiner plate before 114 
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measuring absorbance at 414 nm, using a multi-detection microplate reader Synergy HT. 100 % lysis 115 
was defined as RBC treated with 1% Triton-X 100 and sterile saline treated RBC was added for 116 
baseline adjustments. The test range was 3.1-400 µg/mL. 117 
 118 
MTT assay 119 
Toxicity against HeLa cells was estimated by the MTT viability assay. HeLa cells were cultured in 120 
DMEM Glutamax media (32430-027, Invitrogen), media supplemented with 10% FBS and 1% 121 
pen/strep using standard techniques. The cells were passaged at least 2 times before being used in the 122 
assay, to ensure logarithmic growth. At 80 % confluency, cells were harvested, quantified and 10.000 123 
cells/well were seeded in a 96-well microtitter plate. The cells were placed in a humidified 5% CO2 124 
atmosphere at 37°C for 24 hours. Media was aspirated and the cells were washed with PBS w/o Ca2+ 125 
and Mg2+. A mixture of peptide and DMEM media (100 µl) was added and the cells were incubated in 126 
a humidified 5% CO2 atmosphere at 37°C for 1 hour before wash with PBS with or without Ca
2+ and 127 
Mg2+. MTT (50 µg) dissolved in PBS with or without Ca2+ and Mg2+ was added and the cells were 128 
incubated 90 minutes in a humidified 5% CO2 atmosphere at 37°C. MTT solution was aspirated and 129 
100 µL of DMSO was added to dissolve the formazan crystals before incubating 5 minutes at 37°C. 130 
The absorbance at 540 nm was read in a multi-detection microplate reader Synergy HT. Viability 131 
control was assigned to samples with only HeLa cells and DMEM media and 0 % viability was 132 
assigned to samples with 1 % added Triton-X-100 instead of peptides. The assay was done 3 times with 133 
duplicates and results are the mean of these. Concentrations giving a 50% reduction in metabolism 134 
(IC50), was calculated using equation (I) in Graphpad Prism.  135 
( )( )HillSlopeXLogICY •÷5010+1
100
=      (Eq. I) 136 
 137 
138 
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Killing kinetics 139 
Colony forming units (CFU) counts were monitored for 180 minutes, following peptide exposure at 140 
concentration corresponding to 1×, 2× and 4×MIC. Overnight culture of E. coli ATCC 25922 was 141 
diluted with fresh Mueller Hinton broth and re-grown to mid-log phase before diluting to a turbidity of 142 
OD600 0.1 and loading 90 µL into wells of a flat bottomed 96-well Greiner plate containing 10 µL of 143 
peptides solution. Growth control was assigned to wells without peptide. The content of individual 144 
plates was collected and plated out in duplicate on LB agar plates. Between extractions, the microtitter 145 
plate was sealed and placed at 37°C. LB agar plates were incubated for 18 hours at 30°C and colonies 146 
were counted. The presented results are the mean of 3 independent experiments.  147 
The effect of peptides on bacterial growth was investigated by monitoring optical density (OD) 148 
following peptide exposure. Overnight culture of E. coli ATCC 25922 was diluted with fresh Mueller 149 
Hinton broth and re-grown to mid-log phase before diluting to a turbidity of OD600 0.1. A microtiter 150 
plate was filled with 10 µL of peptide or antibiotic solution per wells, before loading 90 µL of bacterial 151 
suspension. For both peptides and antibiotics, concentrations corresponding to 1×-, 2×- and 4×MIC 152 
were used. OD600 was measured, with a multi-detection microplate reader Synergy HT at 37°C, every 8 153 
minutes for 5 hours with shaking. The readings were baseline corrected against wells with only Mueller 154 
Hinton broth. Comparison between a standard spectrophotometer, with a cuvette length of 1 cm, and 155 
the readings obtained from the plate reader showed a difference with 5-fold lower readings from the 156 
plate reader (data not shown). In order to make readings meaningful, in relation to the correlation 157 
between optical density and concentration of bacterial cells, the readings from the plate reader was 158 
multiplied with a factor of 5. 159 
The effect on both bacterial DNA content and change in cell size after exposure with peptides was 160 
monitored over 180 minutes by flow cytometry. An overnight culture of E. coli ATCC 25922 was 161 
diluted with fresh Mueller Hinton broth and re-grown to mid-log phase before diluting to a turbidity of 162 
OD600 0.1. A total of 90 µL of this bacterial suspension was loaded into a flat bottomed 96-well Greiner 163 
plate for peptide and antibiotic samples and 100 µL for control samples. After extraction of the zero 164 
sample, 10 µL of peptide solution corresponding to 1× and 4× the MIC concentration was added for a 165 
total volume of 100 µL. Two wells were loaded for each treatment to ensure enough bacteria for the 166 
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flow cytometry analysis. Immediately after extraction the samples were put on ice and centrifuged at 10 167 
000 g for 5 minutes at 4°C and resuspended in 100 µL 10 mM Tris HCl pH 7.4 before fixing with 1000 168 
µL 77% ethanol. The following day, the samples were centrifuged at 10 000 g for 5 minutes before 169 
gently removing the supernatant and adding 140 µL staining solution (90 µg/mL Mitramycin and 20 170 
µg/mL ethidium bromide in 10 mM Tris pH 7.4, 10 mM MgCl2). The samples where run on an A10 171 
Bryte Flow Cytometer and when possible, 20 000 events were included in the analysis.  172 
 173 
Membrane depolarization assay 174 
The LIVE/DEAD® BacLight ™ Bacterial Viability Kit (L7012, Invitrogen), was applied to peptide 175 
treated E. coli ATCC 25922, to investigate a visual indication of the membrane permeability 176 
capabilities of the peptides. Overnight culture of E. coli ATCC 25922 was diluted with fresh Mueller 177 
Hinton broth and re-grown to mid-log phase before diluting to a turbidity of OD600 0.1. Then 10 µL of 178 
peptide solution corresponding to a final test concentration of 1× and 4×MIC was added to a flat 179 
bottomed polystyrene Greiner plate before loading 90 µL of bacteria suspension. 100 µL of bacterial 180 
suspension was used as a control. Each well corresponded to one time point for each individual 181 
treatment. The plate was placed at 37°C and the samples were extracted at the indicated time points and 182 
immediately put on ice. The samples were then centrifuged at 10 000g for 5 minutes, and the pellet 183 
resuspended in 100 µL 0.9% ice cold NaCl, to remove interfering media components. Staining solution 184 
(1 µL) was added and incubated for 15 minutes in the dark, before loading to 1% agarose slips on 185 
microscope slides. Staining solution was prepared by adding 5 µL of 3.3 mM Syto-9 dye in DMSO 186 
(Compound A) and 5 µL of 20 mM Propidium iodide in DMSO (Compound B) to 20 µL of sterile 187 
water. Samples were inspected with a Leica DM5000B microscope using a mercury lamp. A filter cube 188 
with excitation filters of 436, 495 and 580 nm and emission filters of 460, 535 and 630 nm was used to 189 
be able to detect both live and dead bacteria.  190 
To verify the findings from microscope pictures with an assay that could characterize the membrane 191 
permeability of the entire bacterial population in the samples, the Live/Dead quantification was 192 
performed. The assay was essentially performed according to the manufacturer’s instructions. After 193 
establishing a standard curve from known ratios of isopopyl killed and live bacteria an overnight 194 
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culture of E. coli ATCC 25922 was diluted with fresh Mueller Hinton broth and re-grown to mid-log 195 
phase before diluting to a turbidity of OD600 0.1. The bacterial solution and peptide solution was mixed 196 
in a 9:1 ratio (vol/vol) in a 96-well polypropylene plate (Cat. No. 3879, COSTAR) and incubated at 197 
37°C. At the indicated timepoints the content of individual wells was extracted, put on ice and then 198 
pelleted at 11 000 g for 8 minutes before being resuspended in 0.9% NaCl and placed on ice again. The 199 
resuspended bacterial suspension was then added to individual wells of flat bottomed 96-well 200 
polystyrene plate and mixed with 100 µL staining solution before incubation in the dark for 15 minutes 201 
and subsequent measurement of fluorescence on a multi-detection microplate reader Synergy HT. 202 
Green fluorescence was excited at 485 nm and the emission detected at 528 nm, whereas the red 203 
fluorescence was excited at 530 nm and detected at 645 nm. Percentage of living cells was obtained by 204 
using equation (II) using the standard curve made from known ratios of live cells. The staining solution 205 
was prepared by adding 3 µL of both compound A and B, for each 1 mL of distilled sterilized water 206 







    (Eq. II) 208 
Liposome preparation 209 
Large unilamellar vesicles (LUVs) was prepared by mixing POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-210 
phosphocholine) and POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol) and in a molar ratio 211 
of 3:7 as a simple mimic of bacterial membranes and POPC:POPG:Cholesterol was mixed in a molar 212 
ratio of 5:2:3 as a simple mimic of mammalian membrane. POPC (770557), POPG (770257) and 213 
Cholesterol were all purchased from Avanti Lipids (Alabaster, Alabama). The lipid mixture was 214 
concentrated on a rotary evaporator and washed 3 times with 99.9 % ethanol to remove residual 215 
organic solvents. The lipid mixture was then dissolved in 4 mL HEPES buffer (10 mM HEPES, 150 216 
mM KCl, 0.03 mM CaCl2, 0.01 mM EDTA, pH 7.4) with 20 mM calcein (C0875, Sigma), for calcein 217 
containing liposomes and 10 mM Tris pH 7.4 for empty liposomes used for CD spectroscopy, followed 218 
by thorough mixing and sonication for 5 minutes to prevent aggregates. Subsequently, the lipid mixture 219 
was vigorously whirlmixed every 10 minutes over the course of 1 hour and finally left at room 220 
temperature for 1 hour, to allow the lipids to anneal. LUVs were prepared by extruding the lipid 221 
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mixture through, two double stacked 100 nm filters, a total of 10 times using a Nitrogen powered 222 
extruder. The calcein containing liposomes were loaded on Sephadex G-50 columns to separate 223 
encapsulated calcein from free calcein and eluted with HEPES buffer. The size of the liposomes was 224 
verified to be approximately 110 nm with a narrow size distribution by dynamic light scattering (DLS) 225 
using a Zetasizer Nano ZS (Malvern, Worcestershire, UK). Malvern DTS v. 5.10 software (Malvern, 226 
Worcestershire, UK) was used for acquisition and analysis. By comparing the end volume with the 227 
starting volume, the dilution of the initial liposome concentration was estimated and that lead to the 228 
anticipation of a stock concentration of 971 µM of the liposomes. 229 
 230 
Calcein release assay 231 
Calcein release was done in a 96-well plate with shielded wells (MicroWell 96 optical bottom plate, 232 
NUNC, Roskilde, DK). 100 µL of peptide diluted in 10 mM HEPES buffer was added and immediately 233 
before measurement of leakage, 80 µL of 45 µM liposome suspension was added for a final liposome 234 
concentration of 20 µM. The liposome concentration was calculated from the starting concentrations of 235 
lipids, taking into account the change in volume during preparation, and assuming a 100% yield from 236 
the sephadex column. Measurements were performed in a FLUOstar OPTIMA plate reader at an 237 
excitation wavelength of 485 nm and an emission wavelength of 520 nm over the course of 1 hour at 238 
37°C. Maximum leakage of liposomes was acquired by lysis with 10% Triton and release following 239 
peptide exposure, was calculated using equation (III), where Fmax denotes fluorescence after addition of 240 
10% Triton, F0 represents background fluorescence of liposomes and F designates the fluorescence 241 















     (Eq. III) 243 
244 




This study aimed at characterizing the bacterial inhibition and antibacterial mode of action of a set of 246 
highly active antimicrobial peptides earlier identified by Fjell et al. 12. The GN peptide library was 247 
screened for antibacterial activity against Gram-negative E. coli ATCC 25922 and P. aeruginosa 248 
ATCC PAO1 and Gram-positive S. aureus ATCC 29213 bacteria. The minimal inhibitory 249 
concentrations of the tested peptides demonstrated a significant spread in activity pattern from 1.5 to 250 
100 µg/mL (Table 1). Potent broad spectrum activity against both Gram-negative and Gram-positive 251 
bacteria was observed for GN-2, GN-4 and GN-6 peptides. For specific activity against E. coli, GN-14 252 
exhibits as good antimicrobial activity as GN-2, GN-4 and GN-6 peptides. Similarly, a pronounced 253 
antimicrobial activity against S. aureus was observed for GN-5 peptide (1.5 µg/mL), and GN-2 and 254 
GN-6 peptides (3.1 µg/mL). However, in respect to a broad spectrum antimicrobial potential, peptide 255 
GN-2 and GN-4 appear as best candidates.  256 
In an attempt to explain the antibacterial peptide properties with classical chemical properties the 257 
hydrophobic moment was measured for all the peptides. This quantitative measure of the peptides 258 
amphipathicity indicates that antibacterial activity increases proportionally with the hydrophobic 259 
moment (Table 1). In order to further characterize the antimicrobial profiles of the GN peptides, their 260 
ability to selectively target bacterial- versus mammalian cells was assessed using hemolytic assay. 261 
Human red blood cells were exposed to different concentrations of GN peptides and the degree of lysis 262 
was evaluated. All peptides resulted in a dose dependent release of hemoglobin, and toxicity is reported 263 
as the highest concentration of peptides resulting in less than 10 % lysis compared to PBS treated 264 
control cells (Table 1). Comparing antibacterial and hemolytic potential, the peptide library clearly 265 
separates into two sub-groups; GN-8, -9, -11 and -12 being hardly hemolytic with low antimicrobial 266 
potential, while the remaining peptides demonstrate an overall higher antibacterial effect yet still only 267 
modest hemolytic activity. Thus, for this set of peptides the tendency to lyse human red blood cells is 268 
highly correlated with the ability to kill bacteria. In comparison, indolicidin, a small 13 amino acids 269 
tryptophan and arginine rich antimicrobial peptide14, is used as an antibacterialreference peptide 270 
indicating that most of the GN peptides have superior selectivity. To further complement the 271 
assessment of the potential toxicity of the GN peptides, a MTT assay was performed on HeLa cells and 272 
the inhibitory concentrations giving 50 % reduction (IC50) of cellular metabolic activity were calculated 273 
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(Table 1). The results are in agreement with the hemolytic activity, thus demonstrating that the 274 
peptides with the highest antimicrobial activities are the peptides exhibiting the greatest metabolic 275 
inhibition in HeLa cells. Hence, peptides GN-2 and GN-4 stand out as most cytotoxic with IC50 values 276 
of 47 and 37 µg/mL, respectively.  277 
To dissect the antimicrobial activity of GN peptides with a range of different assays, GN-2 was chosen 278 
as the most potent peptide with good selectivity index range of 16 to 32. Correspondingly, GN-6 which 279 
structurally differs from GN-2 peptide in the presence of phenylalanine and a patch of 4 consecutive 280 
tryptophan residues was also considered for characterization for the mechanism of bacterial inhibition.  281 
First to differentiate between bactericidal or bacteriostatic mode of antibacterial activity, colony 282 
forming unit counts were monitored for E. coli cultures exposed to 1×, 2×, and 4×MIC concentrations 283 
of GN-2 and GN-6 peptide. This assay illustrated the ability of the different peptide concentrations to 284 
reduce the colony forming unit counts over a period of 180 minutes. The GN-2 peptide demonstrates 285 
fast antimicrobial activity indicated by a decrease of exponentially growing bacteria within the first 40 286 
minutes of exposure (Figure 1). The inhibition proceeds for 80 minutes after which there is a 287 
reestablished bacterial growth observed. Similar pattern is observed for GN-6 peptide with a slightly 288 
delayed inhibition. Bacterial inhibition is concentration dependent for both peptides, even though the 289 
standard error bars for GN-6 peptide at 4×MIC show high experimental variation. 290 
To further elucidate the bacterial inhibition exploited by the peptides, bacterial mass was monitored by 291 
optical density readings at 600 nm over a course of 5 hours. The control bacteria display exponential 292 
growth until 120 minutes after which clear decrease in optical density is observed. There is a 293 
reestablished growth after 180 minutes, indicating that the decrease after 2 hours is not due to limited 294 
nutrition and/or waste build-up (Figure 2). A number of antibiotics were analyzed in parallel for 295 
growth inhibition patters so that the potential bacterial targets of GN-2 and GN-6 peptides could be 296 
elucidated. In addition to the viability experiments of exponentially growing E. coli, the optical density 297 
measurements revealed clear concentration dependent inhibition of the optical density readings when 298 
bacteria were exposed to 1×MIC concentration of both GN-2 and GN-6 peptide when compared to the 299 
untreated bacteria. The inhibition is most pronounced at 2×MIC concentration for both peptides. With 300 
respect to 1×MIC concentration of both peptides, the inhibition pattern is different indicating distinct 301 
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ways of exerting antimicrobial activity halting bacterial growth. Both peptides at 2×MIC concentration 302 
demonstrate low OD measurements indicative of some degree of bacterial lysis.  303 
Flow cytometry analyses were used to characterize the effect of GN-2 and GN-6 peptide on cell size 304 
and DNA content. Exponentially growing E. coli were exposed to 1× and 4×MIC concentrations of 305 
GN-2 and GN-6 peptides and samples were analyzed every 20 minutes over a course of 3 hours for 306 
DNA content per cell mass extrapolated by fluorescence/lightscatter measurements. Untreated E. coli 307 
show fairly constant ratio of DNA per cell size indicative for a healthy growing bacterial population. 308 
Exposure to 1× and 4×MIC concentration of GN-2 gives pronounced initial decrease of DNA content 309 
per cell size as compared with the control samples. After 40 minutes of exposure an increase of DNA 310 
per cell size is observed for samples treated with 4×MIC concentration, referring to the reestablishing 311 
of the DNA content at this point. At 120 minutes the effect of DNA content per cell size follows similar 312 
ratio to that of the control, indicating a possible recovery (Figure 3A). Similar fashion of initial fast 313 
and persistent decrease of DNA per cell size followed by an increase after 40 minutes is observed for 314 
bacteria treated with 1×MIC concentration of GN-6 peptide.  315 
The increase in cell size indicated by the lightscatter measurements observed in the flow cytometry 316 
data (Figure S2) is supported by the microscopy images taken at time zero and 180 minutes for the 317 
control E. coli population. Bacteria treated with GN-2 peptide at 1× and 4×MIC concentration appear 318 
slightly bigger in size than the control bacteria. Clear difference between cells treated with 1× and 319 
4×MIC concentrations of GN-2 peptide is observed by the large areas of cell debris and bacteria 320 
transparency indicating cell lysis in samples treated with 4×MIC (Figure 3C). Upon treatment with 321 
GN-6 peptide at 4×MIC concentrations, there is a clear morphological change presented by cells that 322 
appear long and filamentous but not lysed (Figure 3C). This data is in agreement with the observations 323 
from the flow cytometry analyzes on DNA, size and DNA /size. 324 
Live/dead staining experiments with SYTO9 green-fluorescent nucleic acid stain and propidium iodide 325 
red-fluorescent stain, were used to analyze the membrane permeability capacity of GN-2. Under 326 
conditions where no membrane permeabilizing agent is present, bacteria with intact membranes will 327 
stain green (Figure 4A). The un-treated control cells are naturally predominantly staining green at all 328 
time-points, illustrating a healthy population of bacteria. E. coli exposed to GN-2 peptide at 1×MIC 329 
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concentration at the 10 and 20 minutes time-point, demonstrate about 90 % permeabilized membranes, 330 
thus staining red. However, over time the surviving cells are replicating, resulting in an increasing 331 
percentage of green cells in the later time points (Figure 4B). Upon increasing the GN-2 peptide 332 
concentration to 4×MIC, the membrane integrity stays disrupted throughout the assay of 120 minutes 333 
(Figure 4C). To quantify the membrane permeability in a more un-biased fashion than microscopy, the 334 
same bacterial cultures were also analyzed using a multi-detection fluorescence plate reader. Plotting 335 
the ratio of live and dead cells for cultures incubated with 1×, 2× and 4×MIC concentration of GN-2 336 
peptide over time, clearly demonstrates how 2× and 4×MIC knocks down the viability to around 20% 337 
and this level is kept for 120 minutes. Contrary, at 1×MIC of GN-2, the level of viable bacteria after 10 338 
minutes is about the same as in the samples treated with 2× and 4×MIC of GN-2, but at 1×MIC the 339 
culture re-growths with a doubling time of about 1 hour (Figure 4D).  340 
Due to previously established observation of membrane disruption as a primary mode of action of the 341 
GN peptides, calcein leakage assay was performed. This assay allows characterization of peptides 342 
based on the different potencies to provoke membrane leakage of calcein entrapped unilamellar 343 
phospholipid vesicles (LUVs) made of POPC:POPG (3:7 molar ratio). Calcein is a self-quenching 344 
molecule that at high concentration shows relatively low background fluorescence. As calcein 345 
molecules are being released to the exterior of the vesicles, the fluorescence increases. The percentage 346 
of calcein leakage can be plotted as a function of the concentration of the peptides. All GN peptides 347 
were able to induce calcein leakage in a concentration dependent manner at endpoint reading of 60 min 348 
(Figure 5A). But the release of calcein is much less significant that what is induced by melittin, a well-349 
known peptide with non-selective lytic properties, used as a positive control for giving distinct pattern 350 
of liposome disruption 15. 351 
As it was impossible to distinguish the lytic potential of the different GN peptides using an endpoint 352 
reading the release of calcein over time was monitored, enabling us to extract information about the 353 
capability of the peptides to induce calcein leakage. The GN-2 peptide demonstrates distinct kinetics of 354 
rapidly provoking calcein release from the liposomes, particularly at high concentrations (Figure 5B). 355 
Only a small concentration change from 3.5 µg/mL to 5.5 µg/mL of GN-2, changes the calcein release 356 
from about 30% to 100%. Conversely, the GN-6 peptide, which has slightly lower antimicrobial 357 
activity than GN-2, exerts a much more gradual release of calcein over time, which stabilizes after 358 
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about 10 minutes (Figure 5C). The gradual release is observed for a wider range of concentrations, 359 
suggesting different mode of membrane activity or different modes of action for this peptide compared 360 
to GN-2. This could potentially be reconfirmed and better characterized using the experimental design 361 
of Russel et al. 2010 16. A similar, but even more dramatic profile for gradual release is observed for 362 
GN-14 where gradual increase in calcein leakage progressing over a course of 20 minutes is observed 363 
(Figure 5D). The different patterns of calcein leakage attribute to the correlation of antimicrobial 364 
peptide activity and their ability to disrupt bacterial membranes, where more active peptides cause 365 
more instantaneous release of calcein from the liposome. 366 
The secondary structure of GN peptides and melittin was inspected with circular dichroism (CD) 367 
spectroscopy to see whether or not a confined structure is necessary for the antimicrobial, toxic or 368 
membrane disrupting activities observed. Peptide secondary structures were measured in Tris buffer pH 369 
7.4 and unilamellar phospholipid vesicles consisting of POPC:POPG:Cholesterol (5:2:3 molar ratio) 370 
and POPC:POPG (3:7 molar ratio), the latter mimicking mammalian and bacterial membranes, 371 
respectively (Figure S3). None of the peptides demonstrated any defined secondary structures in Tris 372 
buffer, indicating random coils under these conditions. In presence of LUV that mimic mammalian 373 
membranes, the control peptide melittin adopts a structural confirmation similar to that of an α-helix 374 
with peak minima at 222 and 208 nm 17. Using the DichroWeb K2D algorithm 18, the α-helix content in 375 
melittin was calculated to be 77 % which is in agreement with other publications 19. The CD spectra for 376 
the GN peptides are similar for mammalian and bacterial membrane mimics and illustrate no well-377 
defined secondary structure in either environment. Therefore, it is reasonable to assume that GN 378 
peptides exert their antimicrobial, toxic and membrane disrupting activity without adapting any well-379 
defined secondary structure.  380 
 381 
382 




Due to the increased number of infectious agents that are resistant to many well-known classes of 384 
antibiotics, there is a constant need of improved alternative drug classes and therapies. In this study we 385 
present evaluation of the antimicrobial potencies of ten different peptides, GN-2 to GN-14, from the in 386 
silico optimized peptide library previously reported on by Fjell et al. 12. These peptides are rich in 387 
tryptophan residues along with lysine and arginine in various orders along the backbone (Table 1). The 388 
contribution of the arginine, lysine and tryptophan residues to the antimicrobial activity is exerted by 389 
primary interaction of the charged residues with the net negative charge distributed on the surface of 390 
the bacterial membranes followed by insertion of tryptophan residues in the interfacial region of the 391 
phospholipid bilayer 20. Beneficial features within the GN peptide library that exhibit somewhat higher 392 
antimicrobial activity than others are the cationic and bulky three residues in the amino terminal with 393 
specific annotation to the cationic residues which mediate interaction with the anionic lipids and lead to 394 
membrane instability in Gram-negative bacteria models 21. This observation is further supported with 395 
the GN peptides -8, -9, -11 and -14 which have either leucine or isoleucine in addition to one cationic 396 
(either lysine or arginine) and one tryptophan residues within their structure and exhibit lower 397 
antimicrobial activities.  398 
To understand the overall activity of the GN peptides and their ability to selectively discriminate 399 
between bacterial and mammalian membranes, and therefore obtain a selectivity index as a ranking tool 400 
for the most potential peptide candidate, hemolytic and toxic effects were investigated. A strong 401 
relationship between hydrophobicity and high antimicrobial activity and high toxicity has been reported 402 
in the literature22. Such observation could not be observed in this study for the GN peptides. GN-2 and 403 
GN-4 are the most active against both Gram-positive and Gram-negative bacteria and have both high 404 
hemolytic profiles. They share the same charge distribution along their backbone differing only in 405 
isoleucine (GN-2) and leucine (GN-4) at the C-terminal end and arginine (GN-2) and lysine (GN-4) at 406 
the 4th position. The last feature suggests that the lysine residue in GN-4 peptide, which is previously 407 
ascribed as a contributor to the higher lytic effects 21, exerts the same effect when compared to arginine 408 
in GN-2 peptide (Table 1).  409 
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For a better differentiation of host cell toxicity, metabolic activities in HeLa cells were also monitored. 410 
Comparing toxicity against HeLa cells with the hemolytic properties of the GN peptides, reveals a 411 
disproportionally high toxicity towards the former (Table 1). This could be related to the peptides 412 
exerting higher selectivity to the more anionic cancer cells, similar to previous observations 23. In 413 
addition, peptides that successfully entered HeLa cells could target intracellular membranes that 414 
resemble bacterial membrane such is the mitochondrial membrane and therefore inhibit metabolism 415 
that could be lethal to eukaryotic cells 24. To further elucidate the observed toxicity of GN-2 and GN-4, 416 
peptides toxicity measurements on a non-cancerous mammalian cells or animal studies should be 417 
employed. 418 
The current study demonstrate a fast decrease of exponentially growing E. coli when exposed to sub-419 
MIC concentrations of both peptide GN-2 and GN-6 (Figure 1 and 2). The observed decrease is 420 
probably due to metabolic disturbance that halts bacterial growth for about 80 minutes, after which the 421 
growth is reestablished. This is also in agreement with the OD measurements, which revealed similar 422 
decrease in the bacteria growth under the same conditions. Flow cytometry analysis show that over a 423 
period of 80 minutes the cell size at MIC concentrations does not change significantly, thus supporting 424 
the above stated evidence (Figure S2). In support of this, the microscopic images reveal no obvious 425 
morphological difference except that the MIC treated samples appear slightly bigger in size. The 426 
increase in cell size is a result of metabolic inhibition which delays the decrease in cell size which is 427 
normally observed when bacterial suspension gets denser 25. In contrast to the bacteriostatic inhibition 428 
at MIC concentration of both the GN-2 and GN-6 peptide, bactericidal inhibition is observed at 4×MIC 429 
concentrations. Inhibition through bacterial lysis is ascribed to GN-2 peptide which causes decrease in 430 
OD of E. coli over time, and such relationship has also been described in the literature 26. The 431 
mechanism behind the bactericidal killing for GN-6 demonstrates no signs of lysis rather than 432 
filamentation which are reported as an increase in the lightscatter from the flow cytometry analysis 27. 433 
These results are further corroborated by the microscopy studies. Prior studies have shown that the SOS 434 
response to ciprofloxacin and beta-lactams is ascribed to filamentation 28and the same can be induced 435 
by multiple environmental stresses 29.  436 
Disturbed membrane integrity of E. coli is observed after 10-20 minutes of exposure of 1×MIC 437 
concentration of GN-2 peptide, followed by gradual reestablishment or growth of cells that survived 438 
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the initial attack (Figure 4). The latter seems plausible as cells surviving exposure to the peptide would 439 
be in a rough and rather hostile environment, thus explaining their very slow growth. The phenomena 440 
observed between 40 and 80 minutes, does also correlates with the observations of constant cell size 441 
from flow cytometry analysis and a standstill in CFU. However, using live/dead staining analysis the 442 
reestablishment of membrane integrity has been ascribed to membrane reassembly which leads to 443 
propidium iodide exclusion 30 or possible efflux pumps that drive propidium iodide out of the cell 31. 444 
The later mechanism would require presence of ATP for efflux pumps which could be in agreement 445 
with membrane leakage and escape of ions upon peptides acting on membranes at low concentrations, 446 
provoking ATP production 32. In summary, it may seem as GN-2 induce sufficient membrane 447 
permeabilization for the entry of propidium iodine, but the process does not translate into full loss of 448 
viability. In relation to this observation, prior studies have shown that Bac8c, a peptide with sticking 449 
resemblance to the GN peptides, can causes membrane depolarization after 5 minutes of exposure 450 
followed by membrane recovery after 90 minutes 33. In case of 2× and 4×MIC concentrations of GN-2 451 
peptide, the peptide consistently causes membrane leakage supported by the visual and quantitative 452 
membrane leakage assays supported by CFU counts that show loss of bacterial viability (Figure 3 and 453 
4). 454 
The GN-2 peptide with a very narrow concentration range from 5.5 to 1.7 µg/mL induced instant 455 
release of calcein from model membranes, corresponding to 100% and 5%, respectively (Figure 5). 456 
This observation coincides with a proposed model of membrane active antimicrobial peptides binding 457 
to the surface of the phospholipids parallel to the membrane (S-state) and upon reaching a threshold 458 
change their orientation into perpendicular position (I-state), thereby inducing a more profound 459 
membrane disruption 32. The GN-14 peptide revealed a more gradual release of calcein content which 460 
progresses over a period of 20 minutes. Such release has been ascribed to a mechanism of transient 461 
pore formation 34where liposomes re-stabilize resulting in plateau state of calcein release 34-35, leaving 462 
partially depleted liposomes. Given that the GN peptides only are composed of 9 amino acids, the 463 
toroidal pore model is the more plausible mechanism of membrane action due to the fact that the pores 464 
in this model are stabilized by both lipids and peptides rather than only peptides as in the barrel-stave 465 
model 34. A membrane mechanism involving toroidal pores are further supported by the lack of well 466 
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defined secondary structures in the GN peptide library (Figure S3), and none helical peptides have also 467 
by others been demonstrated to work through this mechanism 36. 468 
Previous studies have shown that melittin is a pore forming membrane active peptide that acts in an all 469 
or none manner 19c, 37, resulting in these immediate release profiles of calcein. Since the current study 470 
showed similar kinetics in mediating calcein release for both melittin and GN-2, it is reasonable to 471 
assume that the GN-2 peptide also acts by pore formation mechanism. However the calcein release for 472 
mellitin is much more pronounced at lower concentrations when compared to the release for peptide 473 
GN-2 Fig.5A. Having said that it is important to stress out that melittin and GN-2 act with different 474 
potencies of 16.3 (3.5 µg/mL) lipid/peptide molar ratio for melittin and 5.4 (5.5 µg/mL) for the GN-2 475 
peptide. Furthermore, we would argue that GN-6 which results in a much more gradual release of 476 
calcein, also could work through pore formation. The difference in kinetics of these peptides (GN-2 477 
and GN-6) might be related to the lifetime of the pores 35, 38, the size of the pores and the number of 478 
pores 38, all of which reflects on the release of the entrapped molecules from the LUVs. Even though 479 
pore formation may seem the best mechanism of action of tested GN peptides, the possibility of 480 
membrane disruption exploited by a mixture of different mechanism should not be excluded 39. The 481 
release of calcein for both peptides, GN-2 and GN-6, levels off over time (Figure 5B-C) and this type 482 
of behavior has been reported to indicate transient pore formation during the initial insertion step into 483 
the lipid bilayer 34. 484 
In conclusion, based on the experimental data obtained in the current study the primary antibacterial 485 
mechanism of action of GN-2 and GN-6 is associated with membrane permeabilization at high peptide 486 
concentrations with different kinetics and potencies. At more moderate peptide concentrations it 487 
appears that the peptides affect on metabolic disturbance, and further work is required to strengthen 488 
these observations. 489 
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Figure 1. Viability of exponentially growing E. coli ATCC 25922 exposed to 1x, 2x, and 4x MIC concentrations 
of (A) GN-2 peptide and (B) GN-6 peptide over a course of 3 hours. Data represent mean and SEM of 3 
independent experiments.  
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Figure 2. Optical density measurements of exponentially growing E. coli ATCC 25922 over 5 hours. Data 
presents mean of 3 independent experiments based. Bacterial growth at 37°C in a 96-well plates from a 
starting inoculum of OD600 of 0.1 has been measured with 8 minutes intervals. (A) Bacteria exposed to 
antibiotics at MIC concentrations, Ampicillin (4 µg/ml), Tobramycin (0.78 µg/ml), Tetracycline (1 µg/ml) and 
Ciprofloxacin (0.05 µg/ml). (B) Bacteria exposed to GN-2 peptide at 1x MIC (6.2 µg/ml) and 2x MIC (12.5 
µg/ml) and GN-6 peptide at 1x MIC (12.5 µg/ml) and 2x MIC (25 µg/ml) concentrations.  
42x12mm (600 x 600 DPI)  
 
 




Figure 3. Peptide effect on E. coli morphology. (A,B) Flow cytometry data of GN-2 and GN-6 peptide 
influence on the DNA content per cell mass represented by fluorescence/lightscatter ratio, respectively. Data 
collected over a course of 3 hours in a microtitter plate format with an inoculum of OD600 of 0.1 and 
incubated at 37°C between extractions. (C) Microscope images of ethanol stained flow cytometry samples of 
E. coli treated with GN-2 and GN-6 peptide at 1x and 4xMIC concentration for 3 hours. Bacteria without 
cellular content appear transparent. Pictures taken at same magnification with a Leica DM5000 B 
microscope.  
87x113mm (600 x 600 DPI)  
 
 




Figure 4. Visualization and quantification of membrane permeabilization of GN-2 peptide on E. coli ATCC 
25922 over a period of 120 minutes. (A) Control cells. (B) Bacteria exposed to 1xMIC GN-2 peptide. (C) 
Bacteria exposed to 4xMIC GN-2 peptide. (D) Percentage of live bacteria after treatment with 1x, 2x and 
4xMIC concentration of peptide GN-2. Pictures taken with Leica DM5000B microscope using mercury lamp.  
118x138mm (600 x 600 DPI)  
 
 




Figure 5. Calcein release from POPG:POPC vesicles. (A) Calcein leakage measurements from 20 µM 
POPG:POPC (7:3) vesicles at 37°C at various peptide concentrations in a 96-well format assay at 60 min. All 
readings are baseline corrected by subtracting values from wells containing only liposomes. 100% leakage is 
estimated as a total calcein release from liposomes exposed to 10 % Triton X-100. Represented results are 
mean values of three independent experiments with good reproducibility. Standard error bars are omitted 
for clarity. Calcein leakage measurements from 20 µM POPG:POPC (7:3) vesicles at 37°C at various 
concentrations of (B) GN-2, (C) GN-6 and (D) GN-14, in a 96-well format assay over a period of 1 hour.  
76x74mm (600 x 600 DPI)  
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Minimal Inhibitory Concentration 
(µg/ml) 
< 10 % 
Hemolysis 
IC50 
time (min) E. coli P. aeruginosa S. aureus 
GN-2 RWKRWWRWI-CONH2 6.33 5.4 6.2 3.1 3.1 100 47 
GN-3 KWWRWRRWW-CONH2 6.62 3.3 12.5 25 6.2 100 106 
GN-4 RWKKWWRWL-CONH2 6.54 5.5 6.2 3.1 6.2 100 37 
GN-5 KKRWWWWWR-CONH2 7.10 2.8 12.5 6.2 1.5 100 131 
GN-6 RKRWWWWFR-CONH2 7.08 2.8 12.5 6.2 3.1 100 97 
GN-8 IWKRWWWKR-CONH2 4.54 2.2 25 100 50 > 400 199 
GN-9 RIWKIWWKR-CONH2 4.63 4.8 25 25 > 50 > 400 > 200 
GN-11 IKWKRWWWR-CONH2 5.88 3.4 12.5 50 25 > 400 > 200 
GN-12 KWWKIWRWR-CONH2 6.13 2.9 25 12.5 12.5 > 400 173 
GN-14 RLWKRWWIR-CONH2 4.43 4.4 6.2 100 25 100 > 200 
Indolicidin ILPWKWPWWPWRR-CONH2 ND 1.2 25 100 12.5 100 > 200 
 
Table 1: Hydrophobic moment is a quantitative measure of amphipathicity calculated with HydroMCalc using the CCS scale. Median 
MIC values of GN peptides in µg/ml against E. coli ATCC 25922, P. aureginosa PA01 and S. aureus ATCC 29213 obtained by 3 
repeated experiments. Hemolysis values are the mean concentration in µg/ml recorded over 3 experiments that induced less than 10% 
hemolysis. IC50 values in µg/ml is a toxicity measurement resulting from the MTT assays performed on HeLa cells, and calculated 
from the equation Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)).  
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Figure 1. Viability of exponentially growing E. coli ATCC 25922 exposed to 1x, 2x, and 4x MIC 
concentrations of (A) GN-2 peptide and (B) GN-6 peptide over a course of 3 hours. Data represent 
mean and SEM of 3 independent experiments.  
 
Figure 2. Optical density measurements of exponentially growing E. coli ATCC 25922 over 5 
hours. Data presents mean of 3 independent experiments based. Bacterial growth at 37°C in a 96-
well plates from a starting inoculum of OD600 of 0.1 has been measured with 8 minutes intervals. 
(A) Bacteria exposed to antibiotics at MIC concentrations, Ampicillin (4 µg/ml), Tobramycin (0.78 
µg/ml), Tetracycline (1 µg/ml) and Ciprofloxacin (0.05 µg/ml). (B) Bacteria exposed to GN-2 
peptide at 1x MIC (6.2 µg/ml) and 2x MIC (12.5 µg/ml) and GN-6 peptide at 1x MIC (12.5 µg/ml) 
and 2x MIC (25 µg/ml) concentrations.  
 
Figure 3. Peptide effect on E. coli morphology. (A,B) Flow cytometry data of GN-2 and GN-6 
peptide influence on the DNA content per cell mass represented by fluorescence/lightscatter ratio, 
respectively. Data collected over a course of 3 hours in a microtitter plate format with an inoculum 
of OD600 of 0.1 and incubated at 37°C between extractions. (C) Microscope images of ethanol 
stained flow cytometry samples of E. coli treated with GN-2 and GN-6 peptide at 1x and 4xMIC 
concentration for 3 hours. Bacteria without cellular content appear transparent. Pictures taken at 
same magnification with a Leica DM5000 B microscope.  
 
Figure 4. Visualization and quantification of membrane permeabilization of GN-2 peptide on E. 
coli ATCC 25922 over a period of 120 minutes. (A) Control cells. (B) Bacteria exposed to 1xMIC 
GN-2 peptide. (C) Bacteria exposed to 4xMIC GN-2 peptide. (D) Percentage of live bacteria after 
treatment with 1x, 2x and 4xMIC concentration of peptide GN-2. Pictures taken with Leica 
DM5000B microscope using mercury lamp. 
 
Figure 5. Calcein release from POPG:POPC vesicles. (A) Calcein leakage measurements from 20 
µM POPG:POPC (7:3) vesicles at 37°C at various peptide concentrations in a 96-well format assay 
at 60 min. All readings are baseline corrected by subtracting values from wells containing only 
liposomes. 100% leakage is estimated as a total calcein release from liposomes exposed to 10 % 
Triton X-100. Represented results are mean values of three independent experiments with good 
reproducibility. Standard error bars are omitted for clarity. Calcein leakage measurements from 20 
Page 29 of 30 Biopolymers: Peptide Science
µM POPG:POPC (7:3) vesicles at 37°C at various concentrations of (B) GN-2, (C) GN-6 and (D) 
GN-14, in a 96-well format assay over a period of 1 hour. 
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